COVID-19 and the Immunocompromised Patient
ACPE Activity Number: 0204-0000-22-050-L01-P
Release Date: April 12, 2022
Expiration Date: April 12, 2025
Activity Type: Knowledge-based
CE Credits: 1.0 hour, (0.1 CEU) no partial credit
Activity Fee: Free
Activity Overview
In this panel discussion, our content matter experts review the most current therapies available for prophylaxis and treatment for COVID-19 in immunocompromised patients. They will also share their experiences for identifying and triaging eligible patients, strategies for operationalizing administration, provide guidance on selecting oral versus intravenous therapy, and recommend strategies to provide safe and effective therapies to underserved populations.
Accreditation
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Target Audience
Learning Objectives
After participating in this CPE activity, participants should be able to:
- Describe the current medication regimens for prophylaxis and treatment for the current COVID-19 variants.
- Discuss criteria for identifying patients eligible to receive prophylaxis and treatment regimens and operationalize their administration.
- Summarize guidance on administration of oral antivirals with immunosuppressant medication regimens.
- Identify strategies to provide safe and effective therapies to underserved populations.
Schedule of Activities
Introduction and Announcements Presentation Questions, Answers, and Discussion
Faculty
Oncology Pharmacy Manager
M Health Fairview - Maple Grove; Assistant Professor of Pharmacy
Mayo Clinic College of Medicine
Nicholas Lange, PharmD, BCTXP
Clinical Pharmacy Manager | Kidney/Pancreas Transplantation
NewYork-Presbyterian Hospital/Columbia University Irving Medical Center
Dayna McManus, PharmD, BCPS-AQ ID
Senior Clinical Pharmacy Specialist
Infectious Diseases
Director, PGY2 Infectious Diseases Pharmacy Residency
Yale-New Haven Hospital
Krutika Mediwala Hornback, PharmD
Infectious Diseases/Antimicrobial Stewardship Clinical Specialist
Residency Program Director for PGY2 Infectious Diseases
MUSC Health
Relevant Financial Relationship Disclosure
In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company.
An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience.
-
No one in control of the content of this activity has a relevant financial relationship (RFR) with an ineligible company.
Methods and CE Requirements
This activity consists of recordings of faculty slides presentations, active learning activities, discussion, and handouts. Participants must participate in the activity in its entirety to claim continuing pharmacy education credit online at ASHP eLearning Portal. Follow the prompts online to complete the evaluation, claim credit and view the statement of credit immediately after completing the activity.
Per ACPE requirements, CPE credit must be claimed within 60 days of being earned. Claim your CE at http://elearning.ashp.org. Once you have processed and claimed your CE credit, we encourage you to check your NABP eProfile account to verify your credits were transferred successfully before the ACPE 60-day deadline. It is an electronic direct-report process so your credits should appear in your account within a few minutes. After the 60 day deadline, ASHP will no longer be able to report your credit(s) for this activity.